ReviewNature medicine2022
The landscape of mRNA nanomedicine.
Review in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 235 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
235 citing papers in PubMed, 456 citations in OpenAlex.
- Current landscape of clinical trials for mRNA-based therapeutics.Human vaccines & immunotherapeutics · 2026Review
- Clinical research progress and challenges of vaccine for human papillomavirus-associated cancers.Human vaccines & immunotherapeutics · 2026Review
- mRNA lipid nanoparticle vaccines: current status, challenges and future prospects.Molecular biomedicine · 2026Review
- Accelerated discovery of thermostable mRNA-lipid nanoparticle vaccines using data-efficient AI.Nature biotechnology · 2026Article
- Extracellular vesicles for next-gen therapeutics and drug delivery.Molecular biomedicine · 2026Review
- circRNA-programmed macrophages enable localized antibody therapy.Molecular therapy. Nucleic acids · 2026Article
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
- Engineered outer membrane vesicle-like nanoparticles from Lactobacillus plantarum for oral IL-22 mRNA delivery and treatment of DSS-induced colitis.Molecular and cellular biochemistry · 2026Article
- Programmable protein degraders enable selective knockdown of pathogenic β-catenin subpopulations in vitro and in vivo.Science advances · 2026Article
- Nontoxic mRNA vehicles based on electrically neutral self-assembling peptides.Nature communications · 2026Article
- Resolving Heterogeneity of Targeted Lipid Nanoparticles Through Solution-Based Biophysical Analyses.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Mechanical movements generated by movable lipids break endosomal barriers for enhanced mRNA therapeutics.Science advances · 2026Article
- Splenic dendritic cell-targeting mRNA transfection of H-type ionizable lipid-based LNPs for enhancing tumor immunotherapy.Bioactive materials · 2026Article
- Machine-Learning Microfluidic Minute-Scale Microorganism Metrics Monitoring(M6).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in delivery technologies-powered cancer vaccines.Bioactive materials · 2026Review
- Storage Buffer Composition Impacts Internal Structure, Freeze-Thaw Stability, and Transfection Efficiency of mRNA-Lipid Nanoparticles.ACS nano · 2026Article
- Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy.Molecular therapy. Nucleic acids · 2026Review
- Time- and spatially resolved LNA delivery via thermally controlled SPION technology.Molecular therapy. Nucleic acids · 2026Article
- Engineered T7 RNA polymerase to improve mRNA capping efficiency and reduce dsRNA generation duringMolecular therapy. Advances · 2026Article
- Shellac-Mediated Assembly of Nanoparticles for mRNA Delivery.Advanced healthcare materials · 2026Article
175 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and treatment of a wide range of diseases. The recent success of the two highly efficacious mRNA vaccines produced by Moderna and Pfizer-BioNTech to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research. Challenges related to mRNA stability and immunogenicity, as well as in vivo delivery and the ability to cross multiple biological barriers, have been largely addressed by recent progress in mRNA engineering and delivery. In this Review, we present the latest advances and innovations in the growing field of mRNA nanomedicine, in the context of ongoing clinical translation and future directions to improve clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.